Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
Yufeng Wang,David L Drum,Ruochuan Sun,Yida Zhang,Ling Yu,Lin Jia,Steven J Isakoff,Allison M Kehlmann,Ali Emre Dal,Gianpietro Dotti,Hui Zheng,Cristina R Ferrone,Alphonse G Taghian,Albert B DeLeo,Hanyu Zhang,Youssef Jounaidi,Song Fan,Peigen Huang,Cheng Wang,Jibing Yang,Genevieve M Boland,Ruslan I Sadreyev,LaiPing Wong,Soldano Ferrone,Xinhui Wang
DOI: https://doi.org/10.21203/rs.3.rs-2595410/v1
2023-02-21
Abstract:The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumor is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach massively reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquired early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion. Tumors stressed by DSF/Cu and IR also reprogrammed and reversed immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells (PBMC) of healthy or metastatic breast cancer patients, induced robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a novel therapy for solid tumor.